TESA , in its English acronym, is a consortium project established in 2009 through the collaborative effort of research institutes in Southern Africa and Universities involved in Clinical Trials. It is a network composed of different African and European research centers that collaborate with different levels of development and specialization, but with a complementary Clinical Research scenario. The project was also created as a mechanism to foster research collaboration through investment efforts on a joint path to a stronger and more sustainable clinical research landscape.

​

The TESA network has an overall strategic orientation aimed at creating a framework for collaboration, capacity building and training among consortium members and promoting healthy empowerment and personalized healthcare across the African region.

​

The TESA network has a proven track record in EDCTP-led Research and Development programs which have been established over the past decade among African and European countries that have participated since the first EDCTP programme.

​

Currently, the TESA project is in phase III in terms of implementation of the program financed by the EDCP, the former -

The effectiveness of IPTi has been demonstrated in several previous clinical trials which have shown that it is possible to reduce malaria by 30%, hospital admissions by 23% and anemia by 21%. It is also cost-effective, as the drug used for IPTi (sulfadoxine-pyrimethamine, SP) is inexpensive and IPTi uses an existing distribution system, through the Expanded Vaccination Program (EPI). The World Health Organization (WHO) currently recommends that children be given 3 doses of IPTi in the first year of life, along with childhood vaccines, through EPI.